Skip to main content
. 2021 Oct 14;47:102165. doi: 10.1016/j.redox.2021.102165

Table 4.

SCFAs afford protection against oxidative stress via activation of Keap1-Nrf2 pathway in animal models.

Species Strain/diet SCFA Treatment Key findings References
Rat High-fat diet, 9 weeks Butyric NaB (300 mg/kg), every 2d, 7 weeks ↓HDAC1
↑H3K9ac Nrf2 promoter
↑Nrf2, SOD, GSH
↑Insulin signaling
[91]
Obesity-prone rats Butyric 4% NaB, 12 weeks Reversion of bone loss and body weight gain
↑nuclear Nrf2
↑HO1, NQO1
↑ Nrf2/GSK-3β signaling
↑ PGC-1α, TFAM
[92]
Mouse C57BL/6 (Nrf2-/-) Butyric NaB (5 g/kg/day), 20 weeks ↓ Renal oxidative damage
↓HDAC
↑Nrf2, HO1, NQ1
No Nrf2 nuclear translocation
[93]
C57BL/6 with experimental autoimmune uveitis Butyric NaB orally (1 g/kg/day) 14d ↓ Ocular inflammatory response
↓Th17 cells
↑Treg cells
Nrf2/HO1 dependent
[94]
C57BL/6 (Nrf2-/-) diabetes-induced Butyric NaB (5 g/kg/day) 20 weeks ↓ Aortic endothelial dysfunction Nrf2-dependent
↓HDAC
↑Nrf2 transcript and protein
No significant Nrf2 nuclear translocation
[66]

Abbreviations: ERK: extracellular-signal-regulated kinase; FFAR2: free fatty acids receptor 2; GSH: glutathion; GPX2: glutathione peroxidase 2; GSK-3β: glycogen synthase kinase-3β; GR109A: G-protein-coupled receptor; HDAC1: histone deacetylase 1; HO1: heme oxygenase 1; H3K9ac; histone H3 acetylated in lysine 9/14; ICAM-1: intercellular adhesion molecule 1; IL-1β: interleukin 1 beta; JNK: Jun N-terminal kinase; LRP-1: LDL Receptor Related Protein 1; MCP-1: monocyte chemotactic protein 1; MDA: malondialdehyde; SOD1-3: superoxide dismutase 1–3; NaB: sodium butyrate; NQ1: NAD(P)H: quinone oxidoreductase-1; Nrf2: nuclear erythroid 2-related factor 2; PGC1-α: peroxisome proliferator-activated receptor γ co-activator 1 α; p38: mitogen activated (MAP) kinase p38.

Upward arrow (↑) indicates an increase and downward arrow (↓) a decrease in respective measured outcomes.